Why Research and Preclinical Study Matter
Research and preclinical studies are critical for derisking. They identify viable biological targets (like proteins or genes), screen large compound libraries for potential “hits,” and optimize chemical structures to maximize potency and safety. Preclinical in vitro assays then assess how the lead compound behaves in biological systems—examining factors such as metabolism, toxicity, and cardiac safety—before any human is exposed.
When these steps are rushed or insufficient, the consequences can be disastrous. A notable example is the case of TGN1412, a monoclonal antibody that caused life-threatening immune reactions in human volunteers during its 2006 Phase I trial in the UK. Preclinical testing had failed to detect the severe cytokine storm it triggered. The oversight stemmed from limitations in the animal models and insufficient predictive in vitro assays—ultimately resulting in hospitalization of six volunteers and massive financial and reputational losses for the developer, TeGenero【Source: Suntharalingam et al., N Engl J Med. 2006】
What Parameters Are Evaluated?
In the research phase, techniques like CRISPR-Cas9 screens and proteomics help uncover disease-relevant targets and validate them functionally. High-throughput screening (HTS) and high-content screening (HCS) are then used to find and prioritize compounds that modulate those targets. During the preclinical phase, in vitro studies evaluate drug metabolism (e.g., liver microsomal stability), genotoxicity (Ames test), cardiotoxicity (hERG channel assays), and general cell health (MTT or ATP-based viability tests). These parameters are essential for understanding how a drug behaves in living systems and whether it poses any red flags before clinical testing.
What Are the Golden Standards?
Each of these assessments has a “gold standard.” For target validation, CRISPR-based functional genomics is now preferred due to its precision. HTS remains the benchmark for identifying chemical hits at scale, while HCS allows for rich phenotypic profiling. In preclinical testing, the Ames test for mutagenicity and hERG assays for cardiotoxicity are both globally mandated and validated by regulatory agencies. Liver microsomal stability tests are essential to determine if a compound will be quickly broken down in the body.
What Is Quantum Nuova and Where Does It Fit?
Quantum Nuova, developed by QT Sense, is a breakthrough live-cell assay platform that uses quantum sensing nanodiamonds to map oxidative stress and free radical activity in real time. It offers a non-destructive, high-resolution window into mitochondrial and cellular health—critical pathways for many disease mechanisms and drug actions.
Quantum Nuova has major opportunities across both research and preclinical stages. In research, it can complement HTS and HCS by providing a functional phenotype based on cellular stress—particularly useful for identifying mechanism-of-action insights. In preclinical studies, it can help predict toxicity by detecting early oxidative stress signals in relevant cell types (e.g., liver or cardiac cells), potentially ahead of cell death or other downstream markers.
Who Can Benefit?
Pharmaceutical R&D teams, biotech startups, academic researchers, and CROs can all benefit from Quantum Nuova. Its ability to deliver real-time, label-free insights into cellular stress makes it a valuable addition to both mechanistic and safety studies. It also has strong potential in precision medicine and organoid-based drug screening.
In Summary
Preclinical success relies on precision, scale, and insight—and Quantum Nuova delivers all three. By marrying quantum physics with cellular biology, it opens new possibilities for safer, faster, and more insightful drug discovery.
Looking ahead, integrating non-destructive, real-time assays like Quantum Nuova with high potential clinical translation data could reduce reliance on costly animal models, flag failures earlier, and enable smarter lead selection. If validated at scale, this approach could cut costs, reduce cycle times, and improve prediction accuracy—revolutionizing how the industry approaches preclinical risk.
Share this:
